Key result
Serum resistin level discriminated between simple steatosis and NASH at a cutoff >10.5 with 53.3% sensitivity, 83.3% specificity, and an AUC of 0.73 (p=0.002).
Why the study?
Resistin is linked to insulin resistance, but direct evidence of resistin levels in humans with nonalcoholic fatty liver disease (NAFLD) is lacking.
Can fibroscan and serum resistin levels accurately diagnose nonalcoholic fatty liver disease and discriminate between simple steatosis and NASH?
Case-Control (n=90)
No
Can fibroscan and serum resistin levels accurately diagnose nonalcoholic fatty liver disease and discriminate between simple steatosis and NASH?
Effect estimate: AUC 0.73
p-value: p=0.002
Serum resistin levels and fibroscan scores are significantly correlated and can be used to diagnose NAFLD and differentiate NASH from simple steatosis.
Serum resistin may discriminate NASH from steatosis; leaves open prospective validation before clinical use.
Background: Hormone resistin is linked to the development of insulin resistance, but direct evidence of resistin levels in humans with nonalcoholic fatty liver disease (NAFLD) is lacking. Objective: To study the role of fibroscan and resistin level in diagnosis of nonalcoholic fatty liver patients. Methods: This study was conducted on60 NAFLD patients, 27 patients with nonalcoholic steatohepatitis (NASH), and 33 patients with simple steatosis, who were admitted to Tropical Medicine Department in Shebin El-Kom Fever Hospital and 30 healthy subjects as control. Patients were subjected to meticulous history taking, clinical examination, routine laboratory investigations, abdominal ultrasound, fibroscan, and measurement of serum resistin level. Results: Serum resistin can be used to discriminate between simple steatosis group and NASH group at a cutoff level of > 10.5, with 53.3% sensitivity, 83.3% specificity, 76.1% PPV and 64.1% NPV (AUC = 0.73 and p-value = 0.002). Also, there was a significant difference in fibroscan score in comparison between groups, NASH group represented the highest score. There was a significant relation between serum resistin level and fibroscan score in both NASH and simple steatosis groups. Conclusion: Fibroscan and serum resistin level can be used for diagnosis of nonalcoholic fatty liver and for discrimination between simple steatosis and NASH patients.
No takes yet. Share an insight, caveat, or question.
Soud et al. (2021) conducted a case-control in Non-alcoholic fatty liver disease (NAFLD) (n=90). Serum resistin level and fibroscan vs. Simple steatosis / Healthy controls was evaluated on Discrimination between simple steatosis and NASH (AUC 0.73, p=0.002). Serum resistin level discriminated between simple steatosis and NASH at a cutoff >10.5 with 53.3% sensitivity, 83.3% specificity, and an AUC of 0.73 (p=0.002).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: